NeuroMetrix (NURO) 10-Q5 Nov 242024 Q3 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2024	Nov. 04, 2024
Document Information [Line Items]
Entity Central Index Key	0001289850
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		2,042,689
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Type	10-Q
Entity Current Reporting Status	Yes
Entity Small Business	true
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-33351
Entity Registrant Name	NEUROMETRIX, INC.
Entity Incorporation, State or Country Code	DE
Entity Address, Postal Zip Code	01801
Local Phone Number	890-9989
Entity Filer Category	Non-accelerated Filer
Entity Tax Identification Number	04-3308180
Entity Address, Address Line One	4B Gill Street
Entity Address, City or Town	Woburn
Entity Address, State or Province	MA
City Area Code	781
Stockholders' Equity, Reverse Stock Split	All share amounts in the Quarterly Report on Form 10-Q have been adjusted to reflect a 1-for-8 reverse stock split that was effected on November 21, 2023.
Common Stock [Member]
Document Information [Line Items]
Security Exchange Name	NASDAQ
Trading Symbol	NURO
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Preferred Stock
Document Information [Line Items]
Title of 12(b) Security	Preferred Stock Purchase Rights

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 921,520	$ 1,731,946
Debt Securities, Available-for-Sale	13,913,080	16,265,205
Accounts receivable, net	149,092	518,824
Inventories	1,430,122	1,559,428
Prepaid expenses and other current assets	381,876	779,039
Total current assets	16,795,690	20,854,442
Fixed assets, net	219,106	293,449
Operating Lease, Right-of-Use Asset	147,824	250,150
Other Assets, Noncurrent	26,400	26,400
Total assets	17,189,020	21,424,441
Current liabilities:
Accounts payable	347,641	215,509
Accrued expenses and compensation	719,609	876,739
Operating Lease, Liability, Current	142,621	148,391
Total current liabilities	1,209,871	1,240,639
Operating Lease, Liability, Noncurrent	0	92,485
Total liabilities	1,209,871	1,333,124
Commitments and contingencies
Stockholders’ equity:
Common Stock, Value, Issued	203	152
Additional paid-in capital	232,030,177	229,960,346
Accumulated Other Comprehensive Income (Loss), Net of Tax	83,853	240,171
Accumulated deficit	(216,135,085)	(210,109,353)
Total stockholders’ equity	15,979,149	20,091,317
Total liabilities and stockholders’ equity	$ 17,189,020	$ 21,424,441
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	25,000,000	25,000,000
Common Stock, Shares, Issued	2,033,306	1,524,939
Common Stock, Shares, Outstanding	2,033,306	1,524,939
Convertible preferred stock
Stockholders’ equity:
Preferred stock	$ 1	$ 1
Preferred Non-Convertible Stock
Stockholders’ equity:
Preferred stock	$ 0	$ 0

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
Statements of Operations (Unaudited) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue from Contract with Customer, Including Assessed Tax	$ 587,314	$ 1,203,164	$ 2,450,018	$ 4,583,679
Cost of revenues	275,357	421,382	1,129,125	1,484,240
Gross profit	311,957	781,782	1,320,893	3,099,439
Loss from operations	(1,742,048)	(1,960,898)	(6,824,694)	(5,294,422)
Investment Income, Interest	8,412	25,378	40,579	247,699
Other Nonoperating Income	225,410	166,783	758,383	166,783
Nonoperating Income (Expense), Total	233,822	192,161	798,962	414,482
Net loss	$ (1,508,226)	$ (1,768,737)	$ (6,025,732)	$ (4,879,940)
Earnings Per Share, Basic	$ (0.75)	$ (1.66)	$ (3.10)	$ (4.86)
Earnings Per Share, Diluted	$ (0.75)	$ (1.66)	$ (3.10)	$ (4.86)
Operating expenses:
Research and development	$ 299,739	$ 592,654	$ 1,510,223	$ 2,045,588
Sales and marketing	441,171	943,795	1,937,914	2,504,630
General and administrative	1,313,095	1,206,231	4,697,450	3,843,643
Total operating expenses	$ 2,054,005	$ 2,742,680	$ 8,145,587	$ 8,393,861

Statement of Comprehensive Inco

Statement of Comprehensive Income (Statement) - USD ($)	3 Months Ended		9 Months Ended
Statement of Comprehensive Income (Statement) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net Income (Loss) Attributable to Parent	$ (1,508,226)	$ (1,768,737)	$ (6,025,732)	$ (4,879,940)
Other Comprehensive Income Realized Gain Adjustment	(225,410)	(166,783)	(758,383)	(166,783)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(1,536,544)	(1,730,589)	(6,182,050)	(4,673,071)
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax	$ 197,092	$ 204,931	$ 602,065	$ 373,652

Equity Rollforward Statement

Equity Rollforward Statement - USD ($)	Total	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Preferred Stock Convertible Preferred Stock [Member]	Common Stock [Member]	AOCI Attributable to Parent
Stockholders' Equity Attributable to Parent	$ 23,355,687	$ 226,935,456	$ (203,579,866)	$ 1	$ 96
Shares, Outstanding				200	959,460
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	165,361	165,361
Stock Issued During Period, Shares, Restricted Stock Award, Gross					2,439
Other Comprehensive Income (Loss), Net of Tax	65,874					$ 65,874
Net Income (Loss) Attributable to Parent	(1,574,174)		(1,574,174)
Other Comprehensive Income Realized Gain Adjustment	(166,783)
Net Income (Loss) Attributable to Parent	(4,879,940)
Stockholders' Equity Attributable to Parent	22,012,748	227,100,817	(205,154,040)	$ 1	$ 96	65,874
Shares, Outstanding				200	961,899
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	132,745	132,745
Stock Issued During Period, Shares, New Issues					90,661
Stock Issued During Period, Value, New Issues	691,405	691,396			$ 9
Stock Issued During Period, Shares, Employee Stock Purchase Plans					1,316
Stock Issued During Period, Value, Employee Stock Purchase Plan	8,713	8,713
Stock Issued During Period, Value, Restricted Stock Award, Gross		(1)			$ 1
Stock Issued During Period, Shares, Restricted Stock Award, Gross					9,015
Other Comprehensive Income (Loss), Net of Tax	102,847					102,847
Net Income (Loss) Attributable to Parent	(1,537,029)		(1,537,029)
Stockholders' Equity Attributable to Parent	21,411,429	227,933,670	(206,691,069)	$ 1	$ 106	168,721
Shares, Outstanding				200	1,062,891
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	221,268	221,268
Stock Issued During Period, Shares, New Issues					184
Stock Issued During Period, Value, New Issues	1,426	1,426
Stock Issued During Period, Shares, Restricted Stock Award, Gross					2,820
Other Comprehensive Income (Loss), Net of Tax	38,148					38,148
Other Comprehensive Income Realized Gain Adjustment	(166,783)
Net Income (Loss) Attributable to Parent	(1,768,737)		(1,768,737)
Stockholders' Equity Attributable to Parent	19,903,534	228,156,364	(208,459,806)	$ 1	$ 106	206,869
Shares, Outstanding				200	1,065,895
Stockholders' Equity Attributable to Parent	20,091,317	229,960,346	(210,109,353)	$ 1	$ 152	240,171
Shares, Outstanding				200	1,518,717
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	216,164	216,164
Stock Issued During Period, Shares, New Issues					458,380
Stock Issued During Period, Value, New Issues	1,471,099	1,471,053			$ 46
Stock Issued During Period, Value, Restricted Stock Award, Gross		(1)			$ 1
Stock Issued During Period, Shares, Restricted Stock Award, Gross					6,699
Other Comprehensive Income (Loss), Net of Tax	7,006					7,006
Net Income (Loss) Attributable to Parent	(3,029,574)		(3,029,574)
Other Comprehensive Income Realized Gain Adjustment	(758,383)
Net Income (Loss) Attributable to Parent	(6,025,732)
Stockholders' Equity Attributable to Parent	18,756,012	231,647,562	(213,138,927)	$ 1	$ 199	247,177
Shares, Outstanding				200	1,983,796
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	176,148	176,148
Stock Issued During Period, Shares, Employee Stock Purchase Plans					850
Stock Issued During Period, Value, Employee Stock Purchase Plan	2,601	2,601
Stock Issued During Period, Value, Restricted Stock Award, Gross		(3)			$ 3
Stock Issued During Period, Shares, Restricted Stock Award, Gross					29,453
Other Comprehensive Income (Loss), Net of Tax	(135,006)					(135,006)
Net Income (Loss) Attributable to Parent	(1,487,932)		(1,487,932)
Stockholders' Equity Attributable to Parent	17,311,823	231,826,308	(214,626,859)	$ 1	$ 202	112,171
Shares, Outstanding				200	2,014,099
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	203,870	203,870
Stock Issued During Period, Value, Restricted Stock Award, Gross		(1)			$ 1
Stock Issued During Period, Shares, Restricted Stock Award, Gross					17,610
Other Comprehensive Income (Loss), Net of Tax	(28,318)					(28,318)
Other Comprehensive Income Realized Gain Adjustment	(225,410)
Net Income (Loss) Attributable to Parent	(1,508,226)		(1,508,226)
Stockholders' Equity Attributable to Parent	$ 15,979,149	$ 232,030,177	$ (216,135,085)	$ 1	$ 203	$ 83,853
Shares, Outstanding				200	2,031,709

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Statement of Cash Flows [Abstract]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ (6,025,732)	$ (4,879,940)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	74,343	30,957
Operating Lease, Right-of-Use Asset, Periodic Reduction	102,326	58,087
Stock-based compensation	596,182	519,374
Inventory Charge Cost Of Revenues	74,209	63,420
Investment Income, Net, Amortization of Discount and Premium	0	135,293
Debt Securities, Available-for-Sale, Realized Gain	(758,383)	(166,783)
Changes in operating assets and liabilities:
Accounts receivable	369,732	32,390
Inventories	55,097	(115,042)
Prepaid expenses and other current and long-term assets	363,183	(200,118)
Accounts payable	132,132	(142,608)
Accrued expenses and compensation	(157,130)	356,562
Increase (Decrease) in Operating Lease Liability	(64,275)	(55,373)
Net Cash Provided by (Used in) Operating Activities	(5,238,316)	(4,634,367)
Cash flows from investing activities:
Net Cash Provided by (Used in) Investing Activities	2,954,190	1,058,354
Cash flows from financing activities:
Net proceeds from issuance of stock and warrants	1,473,700	701,546
Net Cash Provided by (Used in) Financing Activities	1,473,700	701,546
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(810,426)	(2,874,467)
Cash and cash equivalents, end of period	921,520
Supplemental disclosure of cash flow information:
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	921,520	1,460,553	$ 1,731,946	$ 4,335,020
Payments to Acquire Debt Securities, Available-for-Sale	(29,045,810)	(22,898,470)
Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale	32,000,000	7,095,000
Proceeds from Maturities, Prepayments and Calls of Held-to-Maturity Securities	0	17,000,000
Payments to Acquire Property, Plant, and Equipment	$ 0	$ (138,176)

Business and Basis of Presentat

Business and Basis of Presentation	9 Months Ended
Business and Basis of Presentation	Sep. 30, 2024
Accounting Policies [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Our Business-An Overview NeuroMetrix, Inc. (the "Company" or "NeuroMetrix") develops and commercializes health care products that utilize non-invasive neurostimulation. Revenues are derived from the sale of medical devices and after-market consumable products and accessories. The Company’s products are sold in the United States and select overseas markets. They are cleared by the U.S. Food and Drug Administration ("FDA") and regulators in foreign jurisdictions where appropriate. The Company has two primary products. DPNCheck® is a point-of-care test for diabetic peripheral neuropathy, which is the most common long-term complication of Type 2 diabetes. Quell is an app-enabled, wearable device for lower extremity chronic pain and for the symptoms of fibromyalgia. The Company held cash, cash equivalents and investment grade securities totaling $14.8 million as of September 30, 2024. The Company believes that its present balance of cash resources and securities coupled with cash inflows from product sales will enable the Company to fund its operations for at least the next twelve months from the date of issuance of the financial statements. Actual cash requirements could differ from management's projections for many reasons, including changes the Company may make to its business strategy, commercial challenges, regulatory developments, changes to research and development programs, supply chain issues, staffing challenges and other items affecting the Company's projected uses of cash. During February 2024, the Company announced that it would undertake a review of its strategic options to maximize shareholder value. These options include changes in marketing strategies, the acquisition of new assets, potential sale of Company assets, and a merger or other strategic transaction. This review process remains ongoing. A timetable for completion of this process has not been established, and even if certain strategic alternatives may be available, the Company cannot provide any assurance that the strategic alternatives review process will result in the successful realization of any particular alternative, transaction or value. Accordingly, the unaudited financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of September 30, 2024, unaudited statements of operations, statements of comprehensive loss, changes in stockholders' equity and cash flows for the quarters ended September 30, 2024 and 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2023 has been derived from the audited balance sheet as of December 31, 2023 included in the Company's Form 10-K referenced below and does not include all disclosures required by U.S. GAAP. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the "SEC"), on March 1, 2024 (File No. 001-33351). Prior period reclassification Certain items in the Statements of Cash Flows from the prior year were reclassified to conform with the current presentation. Revenues Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized at the point in time when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. The Company has a single product delivery performance obligation. Accrued product returns using the most likely amount method are estimated based on historical data and evaluation of current information and variable consideration is not constrained. Revenue from product sales that occur via an online pharmacy agent are recognized on a gross basis and the related fulfillment fees are expensed within cost of revenues. Accounts receivable are recorded in the amount the Company expects to collect, net of the allowance for credit losses. The allowance for credit losses is the Company’s best estimate of the amount of probable credit losses based on customer past payment history, product usage activity, and recent communications with the customer. Individual customer balances which are over 90 days past due are reviewed individually for collectability and written-off when recovery is not probable. The Company does not have any off-balance sheet credit exposure related to its customers. Allowance for credit losses was $25,000 as of September 30, 2024 and December 31, 2023. Two customers accounted for 28% of total revenues in the quarter ended September 30, 2024 and two different customers accounted for 28% of total revenues in the quarter ended September 30, 2023. One customer accounted for 10% of total revenues for the nine months ended September 30, 2024 and two customers accounted for 26% of total revenues in the nine months ended September 30, 2023. Four customers accounted for 74% and three customers accounted for 74% of accounts receivable as of September 30, 2024 and December 31, 2023, respectively. Cash and Cash Equivalents Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in U.S. government securities. Securities The Company invests in highly liquid, marketable debt securities with high credit ratings and typically with maturities of two years or less. Individual securities are designated by the Company as either "held-to-maturity" ("HTM") or “available-for-sale” ("AFS") at the point of investment. Securities classified as short-term have maturities of less than one year. As of September 30, 2024, all marketable securities held by the Company are classified as AFS and had remaining contractual maturities of one year or less. HTM securities are valued on an amortized cost basis and reviewed to determine if an allowance for credit losses should be recorded in the statements of operations. AFS securities are valued at fair value. Unrealized gains and losses on AFS securities are included as a component of accumulated other comprehensive income in the balance sheets and statements of stockholders’ equity and a component of total comprehensive loss in the statements of comprehensive loss. An AFS security may be impaired if its fair value is less than amortized cost. Unrealized losses are evaluated to determine if the impairment is credit-related or non-credit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and a non-credit-related impairment is recognized in other comprehensive loss. For certain types of securities, such as U.S. Treasuries, the Company generally expects zero credit losses. No allowance for credit losses was recorded on its securities portfolio as of September 30, 2024 or December 31, 2023. Fair Value The Company follows the provisions of Financial Accounting Standards Board (the "FASB") Accounting Standards Codification ("ASC") Topic 820-10, Fair Value Measurements and Disclosures ("ASC 820-10"), which defines fair value, establishes a framework for measuring fair value in GAAP and requires certain disclosures about fair value measurements. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC 820-10 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows: Level 1 observable inputs such as quoted prices in active markets; Level 2 inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3 unobservable inputs for which there are little or no market data, which require the Company to develop its own assumptions. The hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value (See Note 5). Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates. Recent Accounting Pronouncements Accounting Standards Updates ("ASUs") issued by the FASB are evaluated for their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or not expected to have a material impact on our financial statements. In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires enhanced disclosures on both an annual and interim basis about significant segment expenses, including for companies with only one reportable segment. This ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. T he Company is currently evaluating the impact of the adoption of this standard on the Company’s Financial Statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
Net Loss Per Common Share	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Common Share	Net Loss Per Common Share Basic and diluted net loss per common share were as follows: Quarters Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Net loss applicable to common stockholders $ (1,508,226) $ (1,768,737) $ (6,025,732) $ (4,879,940) Weighted average number of common shares outstanding, basic and diluted 2,023,280 1,065,003 1,945,995 1,004,339 Net loss per common share applicable to common stockholders, basic and diluted $ (0.75) $ (1.66) $ (3.10) $ (4.86) Shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented: September 30, 2024 2023 Options 62,898 65,037 Unvested restricted stock awards 1,597 7,662 Unvested restricted stock units 92,991 37,706 Convertible preferred stock 8 8 Total 157,494 110,413
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarters Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Net loss applicable to common stockholders $ (1,508,226) $ (1,768,737) $ (6,025,732) $ (4,879,940) Weighted average number of common shares outstanding, basic and diluted 2,023,280 1,065,003 1,945,995 1,004,339 Net loss per common share applicable to common stockholders, basic and diluted $ (0.75) $ (1.66) $ (3.10) $ (4.86)

Investments, Debt and Equity Se

Investments, Debt and Equity Securities	9 Months Ended
Investments, Debt and Equity Securities	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure	Securities The Company's marketable debt securities are classified as either HTM or AFS pursuant to ASC 320 - Investments - Debt Securities . HTM securities are valued at amortized cost. The following table summarizes the valuations and unrealized gains and losses of AFS securities which are recorded at estimated fair value as of September 30, 2024 and December 31, 2023. The Company held no HTM securities as of September 30, 2024 and December 31, 2023. September 30, 2024 Gross Unrealized Available-for-sale securities Cost Gains Losses Credit Losses Estimated Fair Value U.S. government bonds $ 13,829,227 $ 84,435 $ (582) $ — $ 13,913,080 December 31, 2023 Gross Unrealized Available-for-sale securities Cost Gains Losses Credit Losses Estimated Fair Value U.S. government bonds $ 4,412,935 $ 5,665 $ — $ — $ 4,418,600 Commercial paper 11,612,099 234,506 — — $ 11,846,605 Total $ 16,025,034 $ 240,171 $ — $ — $ 16,265,205 The Company evaluates all HTM and AFS securities for impairment at each reporting period. It determined that changes in the fair value of its securities at September 30, 2024 resulted primarily from interest rate fluctuations subsequent to the purchase date of the securities. There was no deterioration in the credit worthiness of the issuers and no credit losses were recorded as of September 30, 2024.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following tables set forth the Company’s financial instruments that were measured at fair value: September 30, 2024 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 666,939 $ 666,939 $ — $ — U.S. government bonds 13,913,080 13,913,080 — — Total $ 14,580,019 $ 14,580,019 $ — $ — December 31, 2023 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 1,284,290 $ 1,284,290 $ — $ — U.S. government bonds 4,418,600 4,418,600 — — Commercial paper 11,846,605 — 11,846,605 — Total $ 17,549,495 $ 5,702,890 $ 11,846,605 $ —

Inventories

Inventories	9 Months Ended
Inventories	Sep. 30, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: September 30, 2024 December 31, 2023 Purchased components $ 1,130,180 $ 1,151,381 Finished goods 299,943 408,047 $ 1,430,122 $ 1,559,428
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure	Securities The Company's marketable debt securities are classified as either HTM or AFS pursuant to ASC 320 - Investments - Debt Securities . HTM securities are valued at amortized cost. The following table summarizes the valuations and unrealized gains and losses of AFS securities which are recorded at estimated fair value as of September 30, 2024 and December 31, 2023. The Company held no HTM securities as of September 30, 2024 and December 31, 2023. September 30, 2024 Gross Unrealized Available-for-sale securities Cost Gains Losses Credit Losses Estimated Fair Value U.S. government bonds $ 13,829,227 $ 84,435 $ (582) $ — $ 13,913,080 December 31, 2023 Gross Unrealized Available-for-sale securities Cost Gains Losses Credit Losses Estimated Fair Value U.S. government bonds $ 4,412,935 $ 5,665 $ — $ — $ 4,418,600 Commercial paper 11,612,099 234,506 — — $ 11,846,605 Total $ 16,025,034 $ 240,171 $ — $ — $ 16,265,205 The Company evaluates all HTM and AFS securities for impairment at each reporting period. It determined that changes in the fair value of its securities at September 30, 2024 resulted primarily from interest rate fluctuations subsequent to the purchase date of the securities. There was no deterioration in the credit worthiness of the issuers and no credit losses were recorded as of September 30, 2024.

Accrued Expenses

Accrued Expenses	9 Months Ended
Accrued Expenses	Sep. 30, 2024
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses and Compensation Accrued expenses and compensation consist of the following: September 30, 2024 December 31, 2023 Professional services $ 376,840 $ 298,534 Compensation 99,312 346,245 Severance 54,000 — Clinical 39,782 39,000 Warranty 8,000 9,400 Sales tax 130,308 141,672 Other 11,367 41,888 $ 719,609 $ 876,739

Leases Leases (Notes)

Leases Leases (Notes)	9 Months Ended
Leases Leases (Notes)	Sep. 30, 2024
Leases [Abstract]
Lessee, Operating Leases [Text Block]	Operating Leases The Company's lease on its Woburn, Massachusetts corporate office and manufacturing facilities extends through mid-September 2025 at a monthly base rent of $13,846 and with a 5-year extension option. Future minimum lease payments under this non-cancellable operating lease as of September 30, 2024 are as follows: 2024 $ 41,446 2025 117,431 Total minimum lease payments $ 158,877 Interest, based on a 15% discount rate $ 16,256 Lease obligation, current portion 142,621 $ 158,877 Total recorded rent expense was $50,377 and $49,232, for the quarters ended September 30, 2024 and 2023, respectively. Total recorded rent expense was $151,132 and $147,696 for the nine month periods ended September 30, 2024 and 2023, respectively. The Company records rent expense on its facility lease on a straight-line basis over the lease term. The remaining operating lease term was 11.5 months as of September 30, 2024.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2024
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred stock and convertible preferred stock consist of the following: September 30, 2024 December 31, 2023 Preferred stock, $0.001 par value; 5,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023 $ — $ — Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at September 30, 2024 and December 31, 2023; 200 shares issued and outstanding at September 30, 2024 and December 31, 2023 $ 1 $ 1 2024 equity activity In the first quarter of 2024, the Company issued 458,380 shares of its common stock, under its at-the-market ("ATM") program and realized net proceeds of $1,471,099. As of April 18, 2024, the Company terminated its ATM program. In March 2024, 1,015 unvested restricted stock awards and 5,912 unvested restricted stock units were forfeited due to the employee reduction described in Note 10. In June 2024, the Company issued 850 shares of fully vested common stock with a value of $2,601 pursuant to the Company's Employee Stock Purchase Plan. In the quarter ended June 30, 2024, the Company issued 91,577 restricted stock units under its 2022 Equity Incentive Plan with a value of $376,027. As of September 30, 2024, the Company had outstanding 1,597 unvested restricted stock awards and 92,991 unvested restricted stock units. At December 31, 2023 the Company had outstanding 6,222 unvested restricted stock awards and 60,492 unvested restricted stock units. 2023 equity activity In May 2023, the Company issued 1,563 restricted stock units under its 2022 Equity Incentive Plan with a value of $12,625. In June 2023, the Company issued 90,661 shares of its common stock under its ATM program and realized net proceeds of $691,405. It also issued 1,316 shares of fully vested common stock with a value of $8,715 pursuant to the Company's Employee Stock Purchase Plan. In July 2023, the Company issued 1,470 shares of its common stock, under ATM program for net proceeds of $1,426 and issued 24,500 restricted stock units under its 2004 Stock Option Plan with a value of $22,883.

Restructuring and Related Activ

Restructuring and Related Activities	9 Months Ended
Restructuring and Related Activities	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	. Employee Headcount Reduction The Company incurred severance charges related to a reduction of 10 full time employees in the first quarter of 2024. This reduction was implemented in order to better align staffing with work responsibilities and to reduce operating expenses. Total severance related charges of approximately $580,000 were recorded in the quarter ended March 31, 2024 and cash payments of approximately $25,000 were made at that time. During the quarter ended June 30, 2024 and September 30, 2024, additional severance payments of approximately $334,000 and $167,000, respectively, were made and the remaining accrued severance obligation was approximately $54,000 which will be paid during the remainder of 2024 in accordance with employee contractual agreements. The following table sets forth the quarterly activity in accrued severance. Nine months ended September 30, 2024 Severance Beginning balance $ — Additions 580,427 Amounts paid out (25,427) Balance, March 31, 2024 555,000 Amounts paid out (334,000) Balance, June 30, 2024 221,000 Amounts paid out (167,000) Balance, September 30, 2024 $ 54,000

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($)	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss) Attributable to Parent	$ (1,508,226)	$ (1,487,932)	$ (3,029,574)	$ (1,768,737)	$ (1,537,029)	$ (1,574,174)	$ (6,025,732)	$ (4,879,940)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	During the third quarter of 2024, none of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), and none of our directors or executive officers adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Business and Basis of Present_2

Business and Basis of Presentation (Policies)	9 Months Ended
Business and Basis of Presentation (Policies)	Sep. 30, 2024
Accounting Policies [Abstract]
Unaudited Interim Financial Statements	Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of September 30, 2024, unaudited statements of operations, statements of comprehensive loss, changes in stockholders' equity and cash flows for the quarters ended September 30, 2024 and 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2023 has been derived from the audited balance sheet as of December 31, 2023 included in the Company's Form 10-K referenced below and does not include all disclosures required by U.S. GAAP. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the "SEC"), on March 1, 2024 (File No. 001-33351). Prior period reclassification
Revenues	Revenues Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized at the point in time when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. The Company has a single product delivery performance obligation. Accrued product returns using the most likely amount method are estimated based on historical data and evaluation of current information and variable consideration is not constrained. Revenue from product sales that occur via an online pharmacy agent are recognized on a gross basis and the related fulfillment fees are expensed within cost of revenues. Accounts receivable are recorded in the amount the Company expects to collect, net of the allowance for credit losses. The allowance for credit losses is the Company’s best estimate of the amount of probable credit losses based on customer past payment history, product usage activity, and recent communications with the customer. Individual customer balances which are over 90 days past due are reviewed individually for collectability and written-off when recovery is not probable. The Company does not have any off-balance sheet credit exposure related to its customers. Allowance for credit losses was $25,000 as of September 30, 2024 and December 31, 2023. Two customers accounted for 28% of total revenues in the quarter ended September 30, 2024 and two different customers accounted for 28% of total revenues in the quarter ended September 30, 2023. One customer accounted for 10% of total revenues for the nine months ended September 30, 2024 and two customers accounted for 26% of total revenues in the nine months ended September 30, 2023. Four customers accounted for 74% and three customers accounted for 74% of accounts receivable as of September 30, 2024 and December 31, 2023, respectively.
Cash and Cash Equivalents, Policy	Cash and Cash Equivalents Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in U.S. government securities.
Marketable Securities, Policy	Securities The Company invests in highly liquid, marketable debt securities with high credit ratings and typically with maturities of two years or less. Individual securities are designated by the Company as either "held-to-maturity" ("HTM") or “available-for-sale” ("AFS") at the point of investment. Securities classified as short-term have maturities of less than one year. As of September 30, 2024, all marketable securities held by the Company are classified as AFS and had remaining contractual maturities of one year or less.
Fair Value Measurement, Policy	Fair Value The Company follows the provisions of Financial Accounting Standards Board (the "FASB") Accounting Standards Codification ("ASC") Topic 820-10, Fair Value Measurements and Disclosures ("ASC 820-10"), which defines fair value, establishes a framework for measuring fair value in GAAP and requires certain disclosures about fair value measurements. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC 820-10 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows: Level 1 observable inputs such as quoted prices in active markets; Level 2 inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3 unobservable inputs for which there are little or no market data, which require the Company to develop its own assumptions. The hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value (See Note 5).
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy	Recent Accounting Pronouncements Accounting Standards Updates ("ASUs") issued by the FASB are evaluated for their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or not expected to have a material impact on our financial statements. In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires enhanced disclosures on both an annual and interim basis about significant segment expenses, including for companies with only one reportable segment. This ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. T he Company is currently evaluating the impact of the adoption of this standard on the Company’s Financial Statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
Net Loss Per Common Share (Tables)	Sep. 30, 2024
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarters Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Net loss applicable to common stockholders $ (1,508,226) $ (1,768,737) $ (6,025,732) $ (4,879,940) Weighted average number of common shares outstanding, basic and diluted 2,023,280 1,065,003 1,945,995 1,004,339 Net loss per common share applicable to common stockholders, basic and diluted $ (0.75) $ (1.66) $ (3.10) $ (4.86)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	September 30, 2024 2023 Options 62,898 65,037 Unvested restricted stock awards 1,597 7,662 Unvested restricted stock units 92,991 37,706 Convertible preferred stock 8 8 Total 157,494 110,413

Investments, Debt and Equity _2

Investments, Debt and Equity Securities (Tables)	9 Months Ended
Investments, Debt and Equity Securities (Tables)	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of Available-for-Sale Securities Reconciliation	September 30, 2024 Gross Unrealized Available-for-sale securities Cost Gains Losses Credit Losses Estimated Fair Value U.S. government bonds $ 13,829,227 $ 84,435 $ (582) $ — $ 13,913,080 December 31, 2023 Gross Unrealized Available-for-sale securities Cost Gains Losses Credit Losses Estimated Fair Value U.S. government bonds $ 4,412,935 $ 5,665 $ — $ — $ 4,418,600 Commercial paper 11,612,099 234,506 — — $ 11,846,605 Total $ 16,025,034 $ 240,171 $ — $ — $ 16,265,205

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring and Nonrecurring Basis	The following tables set forth the Company’s financial instruments that were measured at fair value: September 30, 2024 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 666,939 $ 666,939 $ — $ — U.S. government bonds 13,913,080 13,913,080 — — Total $ 14,580,019 $ 14,580,019 $ — $ — December 31, 2023 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 1,284,290 $ 1,284,290 $ — $ — U.S. government bonds 4,418,600 4,418,600 — — Commercial paper 11,846,605 — 11,846,605 — Total $ 17,549,495 $ 5,702,890 $ 11,846,605 $ —

Inventories (Tables)

Inventories (Tables)	9 Months Ended
Inventories (Tables)	Sep. 30, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following: September 30, 2024 December 31, 2023 Purchased components $ 1,130,180 $ 1,151,381 Finished goods 299,943 408,047 $ 1,430,122 $ 1,559,428
Schedule of Available-for-Sale Securities Reconciliation	September 30, 2024 Gross Unrealized Available-for-sale securities Cost Gains Losses Credit Losses Estimated Fair Value U.S. government bonds $ 13,829,227 $ 84,435 $ (582) $ — $ 13,913,080 December 31, 2023 Gross Unrealized Available-for-sale securities Cost Gains Losses Credit Losses Estimated Fair Value U.S. government bonds $ 4,412,935 $ 5,665 $ — $ — $ 4,418,600 Commercial paper 11,612,099 234,506 — — $ 11,846,605 Total $ 16,025,034 $ 240,171 $ — $ — $ 16,265,205

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
Accrued Expenses (Tables)	Sep. 30, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses and compensation consist of the following: September 30, 2024 December 31, 2023 Professional services $ 376,840 $ 298,534 Compensation 99,312 346,245 Severance 54,000 — Clinical 39,782 39,000 Warranty 8,000 9,400 Sales tax 130,308 141,672 Other 11,367 41,888 $ 719,609 $ 876,739

Leases Leases (Tables)

Leases Leases (Tables)	9 Months Ended
Leases Leases (Tables)	Sep. 30, 2024
Leases [Abstract]
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2024 $ 41,446 2025 117,431 Total minimum lease payments $ 158,877 Interest, based on a 15% discount rate $ 16,256 Lease obligation, current portion 142,621 $ 158,877

Statement of Shareholders' Equi

Statement of Shareholders' Equity (Tables)	9 Months Ended
Statement of Shareholders' Equity (Tables)	Sep. 30, 2024
Equity [Abstract]
Schedule of Stock by Class [Table Text Block]	Preferred stock and convertible preferred stock consist of the following: September 30, 2024 December 31, 2023 Preferred stock, $0.001 par value; 5,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023 $ — $ — Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at September 30, 2024 and December 31, 2023; 200 shares issued and outstanding at September 30, 2024 and December 31, 2023 $ 1 $ 1

Restructuring and Related Act_2

Restructuring and Related Activities (Tables)	9 Months Ended
Restructuring and Related Activities (Tables)	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	The following table sets forth the quarterly activity in accrued severance. Nine months ended September 30, 2024 Severance Beginning balance $ — Additions 580,427 Amounts paid out (25,427) Balance, March 31, 2024 555,000 Amounts paid out (334,000) Balance, June 30, 2024 221,000 Amounts paid out (167,000) Balance, September 30, 2024 $ 54,000

Business and Basis of Present_3

Business and Basis of Presentation (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Business and Basis of Presentation (Detail) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Organization And Basis Of Presentation [Line Items]
Accounts receivable, net	$ 149,092		$ 149,092		$ 518,824
Net proceeds from issuance of stock and warrants			1,473,700	$ 701,546
Accumulated deficit	216,135,085		216,135,085		210,109,353
Cash and cash equivalents	921,520		921,520		1,731,946
Prepaid expenses and other current assets	(381,876)		(381,876)		(779,039)
Assets, Current	(16,795,690)		(16,795,690)		(20,854,442)
Liabilities, Current	(1,209,871)		(1,209,871)		(1,240,639)
Operating Lease, Liability, Noncurrent	0		0		(92,485)
Stockholders' Equity Attributable to Parent	15,979,149	$ 19,903,534	15,979,149	19,903,534	20,091,317	$ 17,311,823	$ 18,756,012	$ 21,411,429	$ 22,012,748	$ 23,355,687
Cost of revenues	275,357	421,382	1,129,125	1,484,240
Gross Profit	311,957	$ 781,782	1,320,893	$ 3,099,439
Operating Lease, Right-of-Use Asset	(147,824)		(147,824)		(250,150)
Assets	(17,189,020)		(17,189,020)		(21,424,441)
Accrued Liabilities, Current	(719,609)		(719,609)		(876,739)
Liabilities	(1,209,871)		(1,209,871)		(1,333,124)
Allowance for doubtful accounts	25,000		25,000		25,000
Cash, Cash Equivalents, and Short-term Investments	14,800,000		14,800,000
Debt Securities, Available-for-Sale, Allowance for Credit Loss	0		0		0
Debt Securities, Held-to-Maturity, Allowance for Credit Loss	$ 0		$ 0		$ 0
One Customer \| Revenue \| Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage			10%
Three Customers [Member] \| Accounts Receivable \| Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage					74%
Two Customers \| Revenue \| Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage	28%	28%		26%
Four Customers \| Accounts Receivable \| Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage			74%

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	157,494	110,413
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	8	8
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	62,898	65,037
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	1,597	7,662
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	92,991	37,706

Net Loss Per Common Share Sched

Net Loss Per Common Share Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Net Income (Loss) Attributable to Parent	$ (1,508,226)	$ (1,487,932)	$ (3,029,574)	$ (1,768,737)	$ (1,537,029)	$ (1,574,174)	$ (6,025,732)	$ (4,879,940)
Weighted Average Number of Shares Outstanding, Basic	2,023,280			1,065,003			1,945,995	1,004,339
Weighted Average Number of Shares Outstanding, Diluted	2,023,280			1,065,003			1,945,995	1,004,339
Earnings Per Share, Diluted	$ (0.75)			$ (1.66)			$ (3.10)	$ (4.86)
Earnings Per Share, Basic	$ (0.75)			$ (1.66)			$ (3.10)	$ (4.86)

Investments, Debt and Equity _3

Investments, Debt and Equity Securities (Details) - AFS - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost		$ 16,025,034
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax		240,171
Debt Securities, Available-for-Sale	$ 13,913,080	16,265,205
Debt Securities, Available-for-Sale, Allowance for Credit Loss	0	0
Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss	0	0
Commercial Paper
Debt Securities, Available-for-Sale [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost		11,612,099
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax		234,506
Debt Securities, Available-for-Sale		11,846,605
US Government Agencies Debt Securities
Debt Securities, Available-for-Sale [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost	13,829,227	4,412,935
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax	84,435	5,665
Debt Securities, Available-for-Sale	13,913,080	$ 4,418,600
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$ (582)

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Assets
Debt Securities, Available-for-Sale	$ 13,913,080	$ 16,265,205
Assets, Fair Value Disclosure	14,580,019	17,549,495
Money Market Funds [Member]
Assets
Cash and Cash Equivalents, Fair Value Disclosure	666,939	1,284,290
US Government Agencies Debt Securities
Assets
Debt Securities, Available-for-Sale	13,913,080	4,418,600
Commercial Paper
Assets
Debt Securities, Available-for-Sale		11,846,605
Level 1
Assets
Assets, Fair Value Disclosure	14,580,019	5,702,890
Level 1 \| Money Market Funds [Member]
Assets
Cash and Cash Equivalents, Fair Value Disclosure	666,939	1,284,290
Level 1 \| US Government Agencies Debt Securities
Assets
Debt Securities, Available-for-Sale	13,913,080	4,418,600
Level 2
Assets
Assets, Fair Value Disclosure	$ 0	11,846,605
Level 2 \| Commercial Paper
Assets
Debt Securities, Available-for-Sale		$ 11,846,605

Inventories (Detail)

Inventories (Detail) - USD ($)	9 Months Ended
Inventories (Detail) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Inventory [Line Items]
Purchased components	$ 1,130,180		$ 1,151,381
Finished goods	299,943		408,047
Inventories	1,430,122		$ 1,559,428
Inventory Charge Cost Of Revenues	$ 74,209	$ 63,420

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Professional services		$ 376,840		$ 298,534
Accrued Salaries, Current		99,312		346,245
Restructuring Reserve		54,000		0
Accrued Clinical Current		39,782		39,000
Warranty reserve		8,000		9,400
Other		11,367		41,888
Sales and Excise Tax Payable, Current		130,308		141,672
Accrued expenses		719,609		876,739
Product Liability Contingency [Line Items]
Other		11,367		41,888
Employee Severance [Member]
Payables and Accruals [Abstract]
Restructuring Reserve	$ 555,000	54,000	$ 221,000	$ 0
Product Liability Contingency [Line Items]
Restructuring Charges	$ 580,427	$ 580,000

Leases Leases (Details)

Leases Leases (Details) - USD ($)		3 Months Ended		9 Months Ended
Leases Leases (Details) - USD ($)	Jun. 01, 2018	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Operating Leased Assets [Line Items]
Operating Lease, Weighted Average Discount Rate, Percent		15%		15%
Operating Lease, Expense		$ 50,377	$ 49,232	$ 151,132	$ 147,696
Operating Lease, Right-of-Use Asset		$ 147,824		$ 147,824		$ 250,150
Lessee, Operating Lease, Remaining Lease Term		11 months 15 days		11 months 15 days
Lessee, Operating Lease, Liability, to be Paid, Year One		$ 41,446		$ 41,446
Lessee, Operating Lease, Liability, to be Paid, Year Two		117,431		117,431
Lessee, Operating Lease, Liability, to be Paid		158,877		158,877
Operating Lease Discount		16,256		16,256
Operating Lease, Liability, Current		142,621		142,621		148,391
Operating Lease, Liability, Noncurrent		$ 0		$ 0		$ 92,485
Woburn Lease [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Renewal Term	5 years
Woburn Lease [Member] \| MonthlyRent [Member]
Operating Leased Assets [Line Items]
Operating Lease, Payments	$ 13,846

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended						3 Months Ended						9 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Aug. 31, 2023	Jul. 31, 2023	Jun. 30, 2023	May 31, 2023	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Class of Stock [Line Items]
Stock Issued During Period, Value, Employee Stock Purchase Plan								$ 2,601			$ 8,713
Net proceeds from issuance of stock and warrants													$ 1,473,700	$ 701,546
Common stock, par value (in dollars per share)							$ 0.0001						$ 0.0001		$ 0.0001
Stock Issued During Period, Value, New Issues									$ 1,471,099	$ 1,426	$ 691,405
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans	850				1,316
Stock Issued During Period, Value, Employee Stock Purchase Plan	$ 2,601				$ 8,715
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans								850			1,316
Stock Issued During Period, Shares, New Issues									458,380	184	90,661
Stock Issued During Period, Shares, Restricted Stock Award, Gross							17,610	29,453	6,699	2,820	9,015	2,439
Stock Issued During Period, Value, Restricted Stock Award, Gross							$ 1	$ 3	$ 1		$ 1
Stock Issued During Period, Value, New Issues									$ 46		$ 9
Restricted Stock
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number							1,597						1,597		6,222
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period		1,015
Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number							92,991						92,991		60,492
Stock Issued During Period, Shares, Restricted Stock Award, Gross			172,660	24,500		1,563		91,577
Stock Issued During Period, Value, Restricted Stock Award, Gross			$ 240,000	$ 22,883		$ 12,625		$ 376,027
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period		5,912
At The Market Offering Program [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues				1,470	90,661				458,380
Proceeds from Issuance of Common Stock				$ 1,426	$ 691,405				$ 1,471,099

Preferred Stock and Convertible

Preferred Stock and Convertible Preferred Stock (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Preferred Non-Convertible Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Value of preferred stock issued	$ 0	$ 0
Preferred stock, shares outstanding (in shares)	0	0
Series B Preferred Stock \| Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	147,000	147,000
Preferred stock, shares issued (in shares)	200	200
Value of preferred stock issued	$ 1	$ 1
Preferred stock, shares outstanding (in shares)	200	200

Restructuring and Related Act_3

Restructuring and Related Activities (Details)	3 Months Ended			9 Months Ended
Restructuring and Related Activities (Details)	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated			10
Restructuring Reserve	$ 54,000			$ 54,000	$ 0
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	54,000	$ 221,000	$ 555,000	54,000	$ 0
Restructuring Charges			580,427	$ 580,000
Payments for Restructuring	$ 167,000	$ 334,000	25,427
Employee Severance [Member] \| Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			310,200
Employee Severance [Member] \| Selling and Marketing Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			234,527
Employee Severance [Member] \| General and Administrative Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			4,200
Employee Severance [Member] \| Cost of Sales
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			$ 31,500